Document Detail


Initiation and maintenance of cardiovascular medications following cardiovascular risk assessment in a large primary care cohort: PREDICT CVD-16.
MedLine Citation:
PMID:  23033546     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
Aim: To examine whether use of a standardized cardiovascular disease (CVD) risk assessment recommended by national guidelines is associated with appropriate initiation and maintenance of medication in a large primary care cohort.Methods and design: A total of 90,631 people aged 30-80 years were followed for up to 3 years after a formal CVD risk assessment was undertaken between January 2006 and October 2009, during routine primary care visits in New Zealand. Patients either had prior CVD or had their CVD risk estimated using a modified Framingham prediction equation for fatal or non-fatal CVD events. The individual risk profiles were anonymously linked to national dispensing data for blood-pressure-lowering and lipid-lowering medications in the 6-month period before and in consecutive 6-month blocks after the baseline CVD risk assessment.Results: At baseline, a combination of blood-pressure-lowering and lipid-lowering therapy was already being used by about two-thirds of patients with prior CVD, one-quarter with a 5-year CVD risk greater than 10% (approximately 20% 10-year risk), and one-tenth with CVD risk below this level. Among these previously treated patients, dispensing rates for blood-pressure-lowering, lipid-lowering, or both medications together declined by only 4-16% up to 3 years after baseline assessment, irrespective of risk category. Among patients untreated at baseline, combination therapy was initiated within 6 months for 21% with prior CVD, 16% with 5-year CVD risk greater than 15% (approximately 30% 10-year risk and the national drug-treatment threshold), 10% with 5-year CVD risk between 10 and 14% (approximately 20-29% 10-year risk), and 3% in the lowest risk category. Across the study population, patients with prior CVD had the highest dispensing rates for each category of medication, and incrementally higher dispensing rates were noted as CVD risk group increased.Conclusions: In this primary care cohort, most patients already using CVD medications at the time of the baseline CVD risk assessment maintained treatment over a maximum of 3 years follow up, irrespective of their estimated baseline risk. Among patients untreated at baseline, subsequent dispensing rates were strongly related to estimated CVD risk group. Around 15-20% of untreated patients meeting national drug-treatment criteria commenced combination pharmacotherapy within 6 months of CVD risk assessment.
Authors:
Suneela Mehta; Sue Wells; Corina Grey; Tania Riddell; Andrew Kerr; Roger Marshall; Shanthi Ameratunga; Jeff Harrison; Tim Kenealy; Dale Bramley; Wing Cheuk Chan; Simon Thornley; Gerhard Sundborn; Rod Jackson
Related Documents :
18192296 - The role of sex hormone-binding globulin and androgen receptor gene variants in the dev...
12732776 - Transvaginal hydrolaparoscopic ovarian drilling using bipolar electrosurgery to treat a...
20189556 - Effects of excision of ovarian endometrioma on the antral follicle count and collected ...
18756476 - Hyperandrogenism, ovulatory dysfunction, and polycystic ovary syndrome with valproate v...
18774896 - Prevalence and opinions of hormone therapy prior to the women's health initiative: a mu...
22842506 - Current approaches to anticoagulation for reducing risk of atrial fibrillation-related ...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-10-2
Journal Detail:
Title:  European journal of preventive cardiology     Volume:  -     ISSN:  2047-4881     ISO Abbreviation:  Eur J Prev Cardiol     Publication Date:  2012 Oct 
Date Detail:
Created Date:  2012-10-3     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101564430     Medline TA:  Eur J Prev Cardiol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Affiliation:
University of Auckland, Auckland, New Zealand.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Age- and sex-related effects on ankle-brachial index in a screened cohort of Japanese: the Okinawa P...
Next Document:  Barriers to therapeutic clinical trials enrollment: Differences between African-American and White c...